Latest News

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA February 2015
read more »

Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer November 2014
read more »

Turning down inflammatory response.
Opening up new treatment possibilities.

The body goes to great lengths to maintain a delicate balance between inflammation and immunity.
Too much immune cell activity leads to tissue-destroying inflammatory diseases. Too little immune cell activity leads to infection. Celtaxsys is taking an entirely new approach to inflammatory disease. By developing treatments that reduce inflammation in a tunable manner we are working to bring new hope to patients who suffer from Cystic Fibrosis, Moderately Severe Acne and other life-altering diseases.

...

Drug Pipeline

Our leading drug candidate, orally administered CTX-4430, completed a 96-subject Phase 1 clinical trial in August 2013 and a Phase 1B trial in adult cystic fibrosis patients in October 2014. Oral, once daily CTX-4430 will enter Phase 2 trials for adult cystic fibrosis and moderately severe acne in the first half of 2015.

more about our Drug Pipeline

A Breath of Fresh Air: Treating Cystic Fibrosis

Cystic fibrosis (CF) is an inherited chronic disease that affects the lungs and digestive system of about 70,000 children and adults worldwide (30,000 in the US). CTX-4430 uses a novel approach to reduce airway obstruction by blocking excessive white blood cell influx. By blocking white blood cell influx and activation, CTX-4430 reduces airway degradation caused by inflammation. CTX-4430 has been granted orphan designation in the US and EU for the treatment of cystic fibrosis.

more about our program in CF

Clearly Different: Treatment of Moderately Severe Acne Vulgaris

Moderately Severe Acne denotes a family of chronic inflammatory skin conditions characterized by pustules (raised red lesions containing fluid) and papules (raised red lesions without fluid), which can cause long-term damage and scarring. Thus, treating inflammation is a major goal of moderately severe acne therapy. CTX-4430 works by blocking inflammation at its source, preventing formation of an inflammatory signal called Leukotriene B4 (LTB4). Doing so is expected to yield the following benefits: Decreased swelling and redness of existing moderately severe acne lesions, reduced the formation of new lesions, and limited tissue damage that leads to scarring.

more about our program in Moderately Severe Acne Vulgaris

About Celtaxsys

Celtaxsys is a clinical-stage development company focused on novel therapeutics that treat inflammatory disease through regulation of immune cell migration and activation. Our lead drug candidate, CTX-4430, is a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor – the key enzyme in production of the powerful promoter of inflammation Leukotriene B4 (LTB4).  Both LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in Cystic Fibrosis (CF). CTX-4430 has been shown to be effective in several CF-related, pre-clinical and clinical models and has been well tolerated in healthy volunteers and CF patients. 

Latest News

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA
February 3, 2015
Celtaxsys, Inc., a clinical stage biotechnology company focused on advancing break through medicines to treat inflammatory mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its once daily, oral leukotriene A4 hydrolase inhibitor (CTX-4430) for the treatment of cystic fibrosis (CF).
see press release here

Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer
November 6, 2014
Celtaxsys, Inc. is pleased to announce the appointment of Sanjeev Ahuja, MD, MBA, FACP as Chief Medical Officer, effective November 1, 2014.
see press release here

For More Celtaxsys News please click here